Epidemiology in patients with COPD with depression and sleep disorder and systemic biomakers in depressed COPD patients in Japan

日本患有抑郁症和睡眠障碍的慢性阻塞性肺病患者的流行病学以及抑郁型慢性阻塞性肺病患者的全身生物标志物

• 批准号: 23591130
• 负责人: KAWAYAMA Tomotaka
• 金额: $ 3.33万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591130/
• 关键词: 慢性閉塞性肺疾患; 喫煙; うつ病; 睡眠障害; モノアミン; バイオマーカー; COPD; カナダ; うつ

The prevalence of depression and sleep disorder in patients with COPD was significantly higher than in the controls, and the relative risk of depression and sleep disorder in COPD was 7.6 and 1.8-folds, respectively. The COPD patients with depression had significantly more frequent exacerbations and hospitalizations than those without depression or sleep disorder.The plasma 5-hydroxyindole acetic acid (5-HIAA), metabolite of serotonin, level in depressed COPD patients was significantly higher than in non-depressed COPD patients and non-smokers, but not smokers. The plasma 5-HIAA level was significantly associated with the severity of depression in patients with COPD.The management for depression and sleep disorder is necessary in patients with COPD, and the measurement of plasma 5-HIAA levels may be helpful to detect the depression in patients with COPD.

COPD患者抑郁和睡眠障碍的患病率显著高于对照组，COPD患者抑郁和睡眠障碍的相对危险度分别为7.6和1.8倍。COPD伴抑郁患者急性加重和住院率显著高于无抑郁或睡眠障碍者，抑郁组血浆5-羟吲哚乙酸（5-HIAA）水平显著高于非抑郁组和非吸烟组，但不吸烟组。COPD患者血浆5-HIAA水平与抑郁程度显著相关，对COPD患者进行抑郁和睡眠障碍的管理是必要的，血浆5-HIAA水平的测定有助于COPD患者抑郁的早期诊断。

项目成果

Development of the Japanese version of the COPD Assessment Test

• DOI: 10.1016/j.resinv.2012.05.003
• 发表时间: 2012-06-01
• 期刊: RESPIRATORY INVESTIGATION
• 影响因子: 3.1
• 作者: Tsuda, Tohru;Suematsu, Rika;Aizawa, Hisamichi
• 通讯作者: Aizawa, Hisamichi

特集ガイドラインをふまえ、気管支喘息の病態研究・治療の最前線に迫る「心不全合併喘息の臨床対応はどのようにおこなうか」

基于专题指南，我们走近支气管哮喘病理研究和治疗的最前沿，“临床上该如何应对哮喘并发心力衰竭？”

• 发表时间: 2013
• 期刊: Respiratory Medical Research
• 作者: 川山智隆;木下隆;一木裕子;松永和子;星野友昭
• 通讯作者: 星野友昭

Safety and efficacy of NVA237 once daily in Japanese patients : the GLOW4 trial

NVA237 每天一次在日本患者中的安全性和有效性：GLOW4 试验

• 发表时间: 2012
• 作者: Sekiya M;Kawayama T;Fukuchi Y;Takahashi T;Kaiso T;Ikeda K;Overend T;Banerji D
• 通讯作者: Banerji D

COPDの気道炎症とその制御

COPD 中的气道炎症及其控制

• 发表时间: 2012
• 作者: Koichiro Nozaki;Hiroshi Kagamu;Jun Koshio;Kosuke Ichikawa;Yu Saida;Tomohiro Tanaka;Satoshi Watanabe;Hirohisa Yoshizawa;and Ichiei Narita;川山智隆
• 通讯作者: 川山智隆

Prevalence of depression and sleep disorder in COPD in Japan

日本慢性阻塞性肺病患者抑郁和睡眠障碍的患病率

• 发表时间: 2011
• 作者: Ito K;Kawayama T;Toda R;Fukushima N;Matsunaga K;Hoshino T;Aizawa H
• 通讯作者: Aizawa H